title: Impact of glucose in peritoneal dialysis: saint or sinner?
abstract: Peritoneal dialysis (PD) solutions using glucose as osmotic agent have been used for more than two decades as effective treatment for patients with end-stage renal disease. Although alternative osmotic agents such as amino acids and macromolecular solutions, including polypeptides and glucose polymers, are now available, glucose is still the most widely used osmotic agent in PD. It has been shown to be safe, effective, readily metabolized, and inexpensive. On the other hand, it is widely assumed that exposure of the peritoneal membrane to high glucose concentrations contributes to both structural and functional changes in the dialyzed peritoneal membrane. As in diabetes, glucose, either directly or indirectly through the generation of glucose degradation products or the formation of advanced glycation end products, may contribute to peritoneal membrane failure. Although efforts to reduce glucose toxicity have been made for years, only a few suggestions, such as dual-bag systems with bicarbonate as buffer system, have found broader acceptance. Recently, some interesting new approaches to the problem of glucose-related toxicity have been made, but further investigations will be necessary before they can be used clinically. This review will focus on adverse effects of glucose in PD solutions and summarize different aspects of glucotoxicity and potential therapeutic interventions.
authors.affiliation: Department of Nephrology, Medizinische Poliklinik-Innenstadt, Klinikum der Universität München, Germany. Thomas.Sitter@med.uni-muenchen.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Sitter
authors.forename: Matthias
authors.initials: M
authors.lastname: Sauter
mesh_terms: D015314:Dialysis Solutions / Q000009:adverse effects* / Q000737:chemistry; D005947:Glucose / Q000009:adverse effects* / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D008658:Inactivation, Metabolic; D009995:Osmosis; D010530:Peritoneal Dialysis / Q000295:instrumentation / Q000379:methods*; D010537:Peritoneum / Q000187:drug effects* / Q000378:metabolism
chemical_list: D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D005947:Glucose